Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income.
Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy profile as the share prices have been battered, and the yields are high enough to make some investors wonder whether the market is flashing a warning.
But the deeper read is different as all three companies are still producing cash, all three are still paying their dividends, and in each case the payout remains tied to a business model that is more durable than the stock chart suggests.
Current yields work out to about 5.7% for EPD, 6.5% for Pfizer and 6.8% for UPS at today’s prices.
EPD: Pipeline business built for ugly markets
Enterprise Products Partners is not an oil producer, so it does not live and die with commodity prices.
It is a fee-based midstream operator that gets paid to transport, store and process hydrocarbons through a sprawling US network.
That model matters because it turns EPD into something closer to a toll road than a bet on crude prices.
The company says it has raised its distribution for 27 consecutive years, and its first-quarter 2026 results showed why income investors keep coming back.
Enterprise generated $2.7 billion of distributable cash flow in the quarter and said that cash supported another 2.8% increase in the distribution.
That is the key point for anyone tempted to sell after a slump. EPD’s payout is not being funded by hope or leverage; it is being funded by recurring cash flow.
The company retained $1.5 billion of DCF in the quarter after distributions, money it can use for growth projects, buybacks, or debt reduction.
Pfizer: Market has already priced in a very grim future
Pfizer is the most bruised name in the group. The stock is far below its pandemic-era peak, but the business is not standing still.
Pfizer’s 2025 annual review says revenue came in at $62.6 billion, and the company has continued to lean on cost cuts and its post-Seagen oncology portfolio as it tries to rebuild growth.
It also just declared another $0.43 quarterly dividend, its 350th consecutive quarterly payout.
The market’s problem with Pfizer is not that the story is broken; it is that expectations are extremely low.
The company reaffirmed its 2026 outlook for revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, while continuing to highlight cost savings and new-product momentum.
That leaves room for a re-rating if execution stabilizes.
In other words, investors selling now are not just taking a loss. They are also giving up a 6%-plus yield at a point when the stock is already priced for disappointment.
UPS: Dividend is living through a restructuring
UPS is the hardest of the three to own because the business has been shrinking in places that used to matter a lot.
But the company is clearly in a deliberate restructuring, not an uncontrolled decline.
Its latest quarter showed $21.2 billion in revenue, with management reiterating a 2026 revenue target of about $89.7 billion and an adjusted operating margin goal of 9.6%.
UPS has also said it is cutting Amazon volume sharply, while targeting about $3 billion in year-over-year cost savings in 2026 after roughly $600 million of savings in the first quarter alone.
That matters because the dividend story rests on cash generation.
UPS approved a quarterly dividend of $1.64 per share, and the company’s annual report shows 2025 revenue of $88.7 billion.
The yield is high because the share price is low, not because the payout has already cracked.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult a qualified financial advisor before making any investment decisions.
The post Why selling these 3 dividend stocks could be a mistake appeared first on Invezz